¼¼°èÀÇ ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Chronic Myeloid Leukemia Treatment Global Market Report 2025
»óǰÄÚµå : 1682059
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,390,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,284,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ Ä¡·á ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 7.7%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 131¾ï 2,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº È¿°úÀûÀ̰í Àο뼺ÀÌ ³ôÀº Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇコÄɾî ÁöÃâ Áõ°¡, ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ Ä¡·á¿¡ ´ëÇÑ ÅõÀÚ, °³º°È­ ÀÇ·á È®´ë µî¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹Ãø ±â°£ ÁÖ¿ä µ¿Çâ¿¡´Â Áø´Ü ¹× ½ºÅ©¸®´× °³¼±, ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ÀÇ Çõ½ÅÀû Ä¡·á, Ç¥Àû ¿ä¹ý °³¹ß, ÷´Ü Á¶±â Áø´Ü ¹× ½ºÅ©¸®´×, ¸ð´ÏÅ͸µ ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ.

°ñ¼ö¼º ¹éÇ÷º´ ÀÌȯÀ²ÀÇ »ó½ÂÀº ÇâÈÄ ¼ö³â°£ ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·á ½ÃÀåÀÇ È®´ë¸¦ °ßÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. °ñ¼ö¼º ¹éÇ÷º´Àº °ñ¼ö¿¡ ¹ß»ýÇÏ´Â ¾ÏÀÇ ÀÏÁ¾À¸·Î ´Ù¾çÇÑ Á¾·ùÀÇ Ç÷¾×¼¼Æ÷¸¦ »ý»êÇÏ´Â ¼¼Æ÷¸¦ ħ¹üÇÕ´Ï´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·áÀÇ ÁÖµÈ ¸ñÀûÀº ¹éÇ÷º´ÀÇ ±Ùº» ¿øÀο¡ ´ëóÇÔÀ¸·Î½á °ñ¼ö ±â´ÉÀ» °­È­Çϰí, ±Ã±ØÀûÀ¸·Î´Â Ç÷±¸¼ö ÀúÇÏ¿Í °ü·ÃµÈ ÇÕº´ÁõÀÇ À§ÇèÀ» ³·Ã߸ç, È­Çпä¹ý ¹× À̽ÄÀÇ Çʿ伺À» ÁÙ¿© °ñ¼ö¼º ¹éÇ÷º´ ȯÀÚÀÇ »ýÁ¸À²À» °³¼±ÇÏ´Â °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¸é, 2023³â 1¿ù, ¹Ì±¹ÀÇ ÀÓÀÇ ´ÜüÀÎ ¹Ì±¹¾ÏÇùȸ(American Cancer Society)´Â, 2023³âÁß¿¡ ¼ºÀÎ ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(AML) ȯÀÚ¼ö´Â ¾à 20,380¸í, »ç¸ÁÀÚ¼ö´Â ¾à 11,310¸íÀ¸·Î Æò°¡Çß½À´Ï´Ù. ±× °á°ú °ñ¼ö¼º ¹éÇ÷º´ ¹ß»ý·ü »ó½ÂÀÌ ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·á ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿°»öü ÀÌ»óÀÇ ÀÌȯÀ²ÀÇ »ó½ÂÀº ÇâÈÄ ¼ö³â°£ ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·á ½ÃÀå È®´ëÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿°»öü ÀÌ»óÀº À¯Àü Á¤º¸ÀÇ Áß¿äÇÑ ´ã´çÀÚÀÎ °³ÀÎ ¿°»öüÀÇ ±¸Á¶Àû ¹× ¼öÄ¡Àû ÀÌ»óÀ» Æ÷ÇÔÇϰí ÀÖ¾î ȯÀÚÀÇ ¿¹ÈÄ¿¡ Áß´ëÇÑ ¿µÇâÀ» ¹ÌÄ¡¸ç, ƯÈ÷ CMLÀÇ °æ¿ì º¸´Ù Àû±ØÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é, »ç¿ìµð¾Æ¶óºñ¾Æ¿¡¼­ ½Ç½ÃµÈ Á¶»ç¿¡ ÀÇÇϸé, ¼±Ãµ ÀÌ»óÀÌ ÀÖ´Â ½Å»ý¾Æ 59¸í Áß 39.3%¿¡¼­ ¿°»öü ÀÌ»óÀÌ ÀÎÁ¤µÇ¾î, ½Å»ý¾Æ ÁýÁß Ä¡·á½Ç(NICU) ÀÔ½ÇÀÚ ÀüüÀÇ 2.3%¸¦ Â÷ÁöÇß´ø °ÍÀÌ, ¹Ì±¹À» °ÅÁ¡À¸·Î ÇÏ´Â »ý¹° ÀÇÇÐ Á¤º¸Çаú °è»ê °Ç°­ µ¥ÀÌÅÍ °úÇÐ ¿¬±¸ÀÇ Àü¹® ±â°üÀÎ ±¹¸³ ÀÇÇÐ µµ¼­°ü(NLM)ÀÇ º¸°í·ÎºÎÅÍ ¹àÇôÁ³½À´Ï´Ù. ±× °á°ú ¿°»öü ÀÌ»ó À¯º´·ü Áõ°¡°¡ ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´(CML) Ä¡·á ½ÃÀåÀÇ È®´ë¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Chronic myeloid leukemia (CML) constitutes a form of cancer that exerts its impact on the bone marrow and blood cells. It is characterized by the excessive production of abnormal white blood cells, referred to as granulocytes. The core objective of CML treatment is the management of the disease, alleviation of symptoms, and enhancement of the overall quality of life for patients grappling with this condition.

Treatment options in the domain of chronic myeloid leukemia encompass a range of approaches, including targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplantation. Among these, targeted therapy assumes prominence as a cancer treatment modality focused on specific molecules or pathways integral to the growth and survival of cancer cells. The administration of these treatments can occur through diverse routes, including oral and parenteral methods, and caters to various end-users such as hospitals and specialized clinics, ultimately underscoring the comprehensive nature of CML management.

The chronic myeloid leukemia treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia treatment market statistics, including chronic myeloid leukemia treatment industry global market size, regional shares, competitors with a chronic myeloid leukemia treatment market share, detailed chronic myeloid leukemia treatment market segments, market trends and opportunities and any further data you may need to thrive in the chronic myeloid leukemia treatment industry. This chronic myeloid leukemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic myeloid leukemia treatment market size has grown strongly in recent years. It will grow from $9.2 billion in 2024 to $9.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of chronic myeloid leukemia, growing awareness about cancer treatment, government initiatives, growing research and development activities for chronic myeloid leukemia treatments.

The chronic myeloid leukemia treatment market size is expected to see strong growth in the next few years. It will grow to $13.12 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for effective and more tolerable treatments, rising healthcare spending, investments in chronic myeloid leukemia treatments, growing personalized medicine. Major trends in the forecast period include improved diagnosis and screening, innovative treatments for chronic myeloid leukemia, development of targeted therapies, advanced early diagnosis and screening, monitoring technologies.

The rising incidence of myeloid leukemia is poised to drive the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Myeloid leukemia, a form of cancer originating in the bone marrow, affects the cells responsible for producing various blood cell types. The primary objective of chronic myeloid leukemia (CML) treatment is to enhance bone marrow function by addressing the root cause of leukemia, ultimately lowering the risk of complications related to low blood cell counts, reducing the necessity for chemotherapy and transplants, and improving survival rates among individuals with myeloid leukemia. For instance, in January 2023, the American Cancer Society, a US-based voluntary health organization, estimated that there were approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) in adults during the year 2023. Consequently, the escalating incidence of myeloid leukemia serves as a driving force behind the chronic myeloid leukemia (CML) treatment market's growth.

The rising incidence of chromosome abnormalities is expected to be a key driver behind the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Chromosome abnormalities, which encompass structural or numerical irregularities in an individual's chromosomes-critical carriers of genetic information, have a significant impact on patients' prognoses and may necessitate more aggressive treatments, particularly in cases of CML. For instance, based on a study conducted in Saudi Arabia, it was revealed that chromosome abnormalities were present in 39.3% of 59 newborn infants with congenital anomalies, accounting for 2.3% of total neonatal intensive care unit (NICU) admissions, as reported by the National Library of Medicine (NLM), a US-based institution specializing in biomedical informatics and computational health data science research. Consequently, the increasing prevalence of chromosome abnormalities is driving the expansion of the chronic myeloid leukemia (CML) treatment market.

Prominent companies in the chronic myeloid leukemia (CML) treatment market prioritize the development of groundbreaking diagnostic products to maintain their market presence. An illustrative instance of such innovation is found in the actions of Precipio, Inc., a US-based diagnostic company specializing in cancer diagnostics. For instance, in August 2023, Precipio, Inc. introduced the BCR-ABL 2.0 Panel, specifically designed for chronic myeloid leukemia (CML) diagnosis. This advanced panel plays a pivotal role in identifying the BCR-ABL1 gene, which is crucial for diagnosing CML. It stands out as the most sophisticated BCR-ABL panel, distinguished by its comprehensive coverage, streamlined workflow, reduced costs, and the enhanced quality of patient care. Notably, it includes the detection of ABL1 mutations, eliminating the necessity for a secondary round of testing for the BCR-ABL1 gene and providing highly accurate results. This remarkable innovation significantly shapes the landscape of chronic myeloid leukemia (CML) treatment.

In November 2022, Merck & Co. Inc., a US-based multinational pharmaceutical company, acquired Imago BioSciences for $1.35 billion. This acquisition enhances Merck's ability to develop cutting-edge therapies for hematologic malignancies, positioning the company to address unmet medical needs in cancer treatment, foster growth in a competitive market, and improve patient care. Imago BioSciences Inc., a US-based clinical-stage biopharmaceutical company, specializes in developing innovative treatments for myeloproliferative neoplasms and other bone marrow diseases, including chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia.

Major companies operating in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.

North America was the largest region in the chronic myeloid leukemia treatment market in 2024. The regions covered in chronic myeloid leukemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic myeloid leukemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia treatment market consists of revenues earned by entities by providing diagnosis and staging, medical consultations and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic myeloid leukemia (CML) market also includes sales of imatinib, dasatinib, bosutinib and ponatinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chronic myeloid leukemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic myeloid leukemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chronic Myeloid Leukemia Treatment Market Characteristics

3. Chronic Myeloid Leukemia Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chronic Myeloid Leukemia Treatment Growth Analysis And Strategic Analysis Framework

6. Chronic Myeloid Leukemia Treatment Market Segmentation

7. Chronic Myeloid Leukemia Treatment Market Regional And Country Analysis

8. Asia-Pacific Chronic Myeloid Leukemia Treatment Market

9. China Chronic Myeloid Leukemia Treatment Market

10. India Chronic Myeloid Leukemia Treatment Market

11. Japan Chronic Myeloid Leukemia Treatment Market

12. Australia Chronic Myeloid Leukemia Treatment Market

13. Indonesia Chronic Myeloid Leukemia Treatment Market

14. South Korea Chronic Myeloid Leukemia Treatment Market

15. Western Europe Chronic Myeloid Leukemia Treatment Market

16. UK Chronic Myeloid Leukemia Treatment Market

17. Germany Chronic Myeloid Leukemia Treatment Market

18. France Chronic Myeloid Leukemia Treatment Market

19. Italy Chronic Myeloid Leukemia Treatment Market

20. Spain Chronic Myeloid Leukemia Treatment Market

21. Eastern Europe Chronic Myeloid Leukemia Treatment Market

22. Russia Chronic Myeloid Leukemia Treatment Market

23. North America Chronic Myeloid Leukemia Treatment Market

24. USA Chronic Myeloid Leukemia Treatment Market

25. Canada Chronic Myeloid Leukemia Treatment Market

26. South America Chronic Myeloid Leukemia Treatment Market

27. Brazil Chronic Myeloid Leukemia Treatment Market

28. Middle East Chronic Myeloid Leukemia Treatment Market

29. Africa Chronic Myeloid Leukemia Treatment Market

30. Chronic Myeloid Leukemia Treatment Market Competitive Landscape And Company Profiles

31. Chronic Myeloid Leukemia Treatment Market Other Major And Innovative Companies

32. Global Chronic Myeloid Leukemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia Treatment Market

34. Recent Developments In The Chronic Myeloid Leukemia Treatment Market

35. Chronic Myeloid Leukemia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â